Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2026Blood

MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

CGCarmen GonzálezCGCamila GuerreroMLMarta Larráyoz

Discussion

Loading...

Member takes

Overview

Randomized trial shows MRD dynamics predict survival in newly-diagnosed multiple myeloma, suggesting implications for treatment.

Key Points

  • The research aims to explore how multiple measurable residual disease (MRD) assessments can predict outcomes and determine the timing of immunotherapy in multiple myeloma patients.
  • Computed MRD dynamics using next-generation flow cytometry in 539 newly-diagnosed MM patients with ≥3 assessments.
  • Executed molecular and immune profiling on matched diagnostic and MRD samples.
  • Investigated survival impact of treating persistent MRD vs relapse with anti-BCMA CAR T cells in mouse models.
  • Identified five MRD dynamics subgroups correlating with survival outcomes.
  • Patients with late-sustained MRD response had similar excellent outcomes to those with early-sustained MRD response.
  • MRD dynamics predicted progression more effectively than transplant-eligibility and the R-ISS.

Cite This Study

González et al. (2026) studied this question.

synapsesocial.com/papers/6a65a890d3aea3239cd78d95https://doi.org/10.1182/blood.2026033878
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Measurable residual disease in newly diagnosed multiple myeloma: Experience from a large cohort from an academic medical center2025
  2. 2What remains matters: Real-world impact of measurable residual disease testing in multiple myeloma2025
  3. 3Single-cell multiomics reveals molecular identities and clonal dynamics of MRD progression in Myelodysplastic Syndromes after stem cell transplant2025
  4. 4Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival2025
  5. 5Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy2025 · 6 citations